KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBITDA Margin (2017 - 2026)

Amneal Pharmaceuticals has reported EBITDA Margin over the past 9 years, most recently at 13.76% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 338.0% year-over-year to 13.76%; the TTM value through Dec 2025 reached 13.05%, up 413.0%, while the annual FY2025 figure was 13.05%, 413.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 13.76% at Amneal Pharmaceuticals, up from 8.97% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 22.64% in Q4 2022 and troughed at 35.51% in Q2 2022.
  • A 5-year average of 7.54% and a median of 9.84% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: plummeted -4805bps in 2022 and later soared 4888bps in 2023.
  • Year by year, EBITDA Margin stood at 2.08% in 2021, then skyrocketed by 988bps to 22.64% in 2022, then crashed by -90bps to 2.3% in 2023, then surged by 351bps to 10.38% in 2024, then soared by 33bps to 13.76% in 2025.
  • Business Quant data shows EBITDA Margin for AMRX at 13.76% in Q4 2025, 8.97% in Q3 2025, and 15.37% in Q2 2025.